Notice Number: NOT-DA-05-008

Key Dates
Release Date: March 25, 2005

This notice, Behavioral and Integrative Treatment of Methamphetamine Abuse and Dependence , is an addendum to Program Announcement PA-03-126, at http://grants.nih.gov/grants/guide/pa-files/PA-03-126.html, published in the NIH Guide, May 19, 2003. One purpose of this addendum is to encourage research on the development, refinement and testing of behavioral and integrative (combined or integrated behavioral and pharmacological and/or complementary/alternative) treatments for methamphetamine abuse and dependence. Another purpose of this addendum is to encourage research on the development, refinement and testing of HIV risk-reduction interventions for individuals in treatment for methamphetamine abuse or dependence. The translation of basic behavioral science and neuroscience research into creative new behavioral interventions for individuals addicted to methamphetamine in treatment is especially encouraged. The National Institute on Drug Abuse (NIDA) comprehensively supports the study of behavioral treatments and interventions (including, but not limited to behavioral, cognitive, family, couples, and systems therapies, psychotherapies, counseling approaches, and risk-reduction interventions) that will potentially have a significant impact on reducing drug abuse and addiction and reducing HIV/AIDS risk behaviors. This notice is meant to supplement Program Announcement PA-03-126, which should be consulted in conjunction with this addendum.

Research Objectives

Methamphetamine abuse is becoming increasingly more common, spreading both geographically as well as into new populations. Many behavioral treatments (and combined behavioral and pharmacological treatments) have been shown to be valuable in the treatment of other drugs of abuse, such as cocaine, nicotine, and marijuana. They have been shown to help with promoting initial abstinence from drugs, reducing total drug use, reducing relapse, decreasing HIV risk behaviors, etc. Nonetheless, there is a paucity of research on the treatment of methamphetamine abuse and dependence, and on how to reduce risk for infectious disease among methamphetamine abusers in drug abuse treatment. This notice seeks research applications in areas including, but not limited to:

Stage I Behavioral Treatment Research:

• Developing, modifying, refining, and improving behavioral and integrative treatments for methamphetamine abuse and dependence, pilot testing these treatments, and assessing their behavioral, cognitive, social, and/or neurobiological mechanism(s) of action.
• Developing, modifying or refining behavioral and integrative treatments for new populations (e.g., women, adolescents, and special populations) of methamphetamine abusers, pilot testing these treatments, and assessing their behavioral, cognitive, social, and/or neurobiological mechanism(s) of action.
• Developing, modifying, refining, and improving interventions to reduce HIV (and other infectious disease risk) for methamphetamine abusing people in drug abuse treatment, pilot testing these interventions, and assessing their mechanism(s) of action.
• Translating neuroscience or basic science findings into more potent behavioral approaches to treat methamphetamine dependence and to reduce associated HIV risk, as well as using neuroscience and basic science approaches to elucidate the components of the treatment that are most effective and potent.
• Modifying or refining behavioral treatments to make them more community-friendly' (e.g., more accessible, less costly, less intensive, easier to administer, etc.) but similarly or even more potent.

Stage II Behavioral Treatment Research:

• Testing the efficacy of promising behavioral and integrative treatments for methamphetamine abuse and dependence, and assessing their mechanism(s) of action, in various populations.
• Testing the efficacy of promising infectious disease risk reduction interventions for methamphetamine abusing individuals in drug abuse treatment, and assessing their mechanism(s) of action, in various populations.
• Examining the dose-response of behavioral and integrative treatments for methamphetamine abuse.

Stage III Behavioral Treatment Research:

• Testing, in community settings, behavioral and integrative treatments for methamphetamine abuse and dependence, in various populations.
• Developing methods to train community practitioners to administer efficacious behavioral treatments for methamphetamine dependence.

All applications must use grant application form PHS398 using the standard receipt dates described in the form. Updated instructions to the PHS398 Application are now available at http://grants.nih.gov/grants/forms.htm.

For further information on application preparation, contact Lisa_Onken@nih.gov.

Inquiries

Please direct inquiries on this notice and on PA-03-126 to:

Lisa Onken, Ph.D.
Chief, Behavioral and Integrative Treatment Branch
Division of Clinical Neuroscience, Development, and Behavioral Treatment
National Institute on Drug Abuse
National Institutes of Health
6001 Executive Boulevard, Room 4234 MSC 9593
Bethesda, MD 20892-9593
Phone: (301) 443-2235
FAX: (301) 443-6814

Weekly TOC for this Announcement
NIH Funding Opportunities and Notices

			Department of Health and Human Services (HHS)
NIH... Turning Discovery Into Health® Note: For help accessing PDF, RTF, MS Word, Excel, PowerPoint, Audio or Video files, see Help Downloading Files.